Gujarat Terce Laboratories Limited has reported its unaudited standalone financial results for the third quarter ended December 31, 2025, showing a decline in both revenue and profitability compared to the corresponding period last year. The pharmaceutical company's Board of Directors approved these results at their meeting held on February 4, 2026.

Financial Performance Overview

The company's quarterly performance reflected challenging market conditions, with key metrics showing year-on-year declines across major parameters.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Gujarat Terce Laboratories recorded revenue from operations of ₹3,607.34 lakhs compared to ₹3,787.08 lakhs in the corresponding period of the previous year, representing a decline of 4.75%. Total revenue for the nine-month period stood at ₹3,633.58 lakhs against ₹3,809.18 lakhs in 9MFY25.

Operational Metrics and Cost Structure

The company's expense structure for Q3FY26 totaled ₹1,129.21 lakhs compared to ₹1,177.04 lakhs in Q3FY25. Employee benefit expenses remained the largest cost component at ₹403.29 lakhs for the quarter, slightly higher than ₹397.73 lakhs in the previous year. Purchase of stock in trade was ₹283.40 lakhs, marginally lower than ₹284.44 lakhs in Q3FY25.

Finance costs showed improvement, declining to ₹3.99 lakhs from ₹8.45 lakhs year-on-year. Other expenses decreased to ₹261.93 lakhs from ₹313.14 lakhs in the corresponding quarter of the previous year.

Regulatory Compliance and Corporate Governance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and have undergone limited review by the company's statutory auditor, Shah Doshi Patel & Associates LLP. The results comply with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company operates in a single pharmaceutical segment, and the paid-up equity capital stood at ₹779.13 lakhs as of December 31, 2025, compared to ₹742.03 lakhs in the previous year. The Board meeting commenced at 3:00 p.m. IST and concluded at 4:05 p.m. IST on February 4, 2026.

Gujarat Terce Laboratories Limited has announced a board meeting scheduled for February 4, 2026, to review and approve the company's unaudited standalone financial results for the third quarter and nine months ending December 31, 2025. The pharmaceutical company communicated this development to BSE Limited on December 28, 2025, in accordance with regulatory requirements.

Board Meeting Details

The meeting will be held on Wednesday, February 4, 2026, where the Board of Directors will consider and approve the unaudited standalone financial results for Q3FY26. The company has issued this notification pursuant to Regulation 29 read with Regulation 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Trading Window Closure

In compliance with the company's Code of Conduct for Prevention of Insider Trading in Securities, Gujarat Terce Laboratories has announced the closure of the trading window. The restriction will be effective from January 1, 2026, to February 6, 2026, with both days being inclusive in the closure period.

Regulatory Compliance

The announcement demonstrates the company's adherence to regulatory frameworks governing listed entities. The notification has been made available on the company's official website at https://www.gujaratterce.in/ to ensure transparency and accessibility for all stakeholders. Company Secretary Ashka Solanki has digitally signed the communication on December 28, 2025, at 11:32:54 +05'30', confirming its authenticity and official nature.

This scheduled board meeting represents a routine corporate governance activity as the company prepares to disclose its financial performance for the third quarter of the fiscal year 2026.